Possible effect of thyroid function on anticoagulant response to unfractionated heparin

Pharmacotherapy

Volumn 26, Issue 2, 2006, Pages 285-288

  Badawi, Omar ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b VISICU   (United States)

Author keywords

Anticoagulation; Heparin; Hyperthyroidism; Thyroid; Unfractionated heparin

Indexed keywords

ACETYLCYSTEINE; ANTICOAGULANT AGENT; AZITHROMYCIN; DILTIAZEM; FERROUS SULFATE; FLUTICASONE; GUAIFENESIN; HEPARIN; IPRATROPIUM BROMIDE; LANSOPRAZOLE; LORAZEPAM; OXYBUTYNIN; PROPYLTHIOURACIL; SALBUTAMOL; SALMETEROL; SERTRALINE;

AGE; AGED; ANTICOAGULATION; ARTICLE; CASE REPORT; CAUCASIAN; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; SEX; SMOKING; THYROID FUNCTION; TREATMENT OUTCOME; WEIGHT;

AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEPARIN; HUMANS; HYPERTHYROIDISM; PARTIAL THROMBOPLASTIN TIME; THYROID FUNCTION TESTS;

EID: 32044467353     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.2.285     Document Type: Article

References (23)

1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64-94S.
2. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 1993;119:874-81.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). J Am Coll Cardiol 2002;40:1366-74.
4. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003;107:2884-8.
5. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health-Syst Pharm 1998;552:159-62.
6. White RH, Zhou H, Woo L, Mungall D. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements. Arch Intern Med 1997;157:2468-72.
7. Trujillo TC, Nolan PE Jr, Quan RA, Slack MK, Ewy GA. Optimization of heparin therapy in patients with unstable angina or acute myocardial infarction using a multiple regression-derived dosing nomogram [abstr]. Pharmacotherapy 1996;16:492-3.
8. Hochman JS, Wali AU, Gavrila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999;138:313-18.
9. Hansten PD. Oral anticoagulants and drugs which alter thyroid function. Drug Intell Clin Pharm 1980;14:331-4.
10. Costigan DC, Freedman MH, Ehrlich RM. Potentiation of oral anticoagulant effect of L-thyroxine. Clin Pediatr 1984;23:172-4.
11. Bristol-Myers Squibb. Coumadin (warfarin sodium) package insert. Princeton, NJ; 2002.
12. Stephens MA, Self TH, Lancaster D, et al. Hypothyroidism: effect on warfarin anticoagulation. South Med J 1989;82:1585-6.
13. Paradiso-Hardy FL, Cheung B, Geerts WH. Evaluation of an intravenous heparin nomogram in a coronary care unit. Can J Cardiol 1996;12:802-8.
14. Rainville EC, Airoldi MR, Sheehey JM, Battle RW. A cardiology heparin dosing protocol. Hosp Pharm 1996;31:1596-602.
15. Mungall D, Lord M, Cason S, Treadwell P, Williams D, Tedrick D. Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute coronary syndromes. Am J Cardiol 1998;82:574-9.
16. Shalansky KF, FitzGerald M, Sunderji R, et al. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Pharmacotherapy 1996;16:1076-84.
17. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93:870-8.
18. Gilchrist IC, Berkowitz SD, Thompson TD, Califf RM, Granger CB. Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Am Heart J 2002;144:73-80.
19. Flaker GC, Bartolozzi J, Davis V, McCabe C, Cannon CP. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in myocardial infarction. Arch Intern Med 1994;154:1492-6.
20. Lackie CL, Luzier AB, Donovan JA, Feras HI, Forrest A. Weight-based heparin dosing: clinical response and resource utilization. Clin Ther 1998;20:699-710.
21. Wu H, Lundblad RL, Church FC. Neutralization of heparin activity by neutrophil lactoferrin. Blood 1995;85:421-8.
22. de Swart CAM, Nijmeyer MB, Roelofs JMM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982;60:1251-8.
23. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992;22:359-74.